Read our responses to health and social care related consultations
As a member of the Care and Support Alliance (CSA), we’re calling on government to invest in care and support for people who are deaf or have hearing loss.
We submitted evidence which highlighted the need for innovative approaches to make sure NHS services address the growing prevalence and impact of hearing loss in the years to come.
Although NHS and social care services are making progress in terms of implementing NHS England’s Accessible Information Standard, more work is needed to ensure people who are deaf or have hearing loss realise the full benefits of good communication.
Our response highlighted the need for local authorities to consider the communication needs of people who are deaf or have hearing loss when commissioning services and developing local plans and strategies.
In light of recent hearing aid cuts and variations in service quality, we want NHS England to meet its commitments in the Action Plan on Hearing Loss and provide better support and guidance to CCGs – and to intervene if there is no improvement.
Action on Hearing Loss have submitted a formal consultation response to the draft guideline on the assessment and management of hearing loss in adults published by the National Institute for Health and Care Excellence (NICE). Action on Hearing Loss lobbied for the publication of this guideline and the final version is due to be published in May 2018. The publication of the NICE guideline is vitally important. It reflects the national priority to tackle the growing public health challenge of hearing loss and will further strengthen the case for the prevention and management of hearing loss. It will enable providers and commissioners to recognise the impact of hearing loss on individuals, and the economic burden that unaddressed hearing loss places on the health and social care system. When put into practice, these guidelines have the potential to effectively target health and care resources to significantly improve patient outcomes, in line with the best available evidence of clinical and cost-effectiveness.